ICCCHealthcare · BiotechnologyTicker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 94 of 100 as at 22 Aug 2026 — among the strongest tenth.
Consensus tells you what everyone already believes. The model scores ImmuCell Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (96): Reported profit is backed by cash, and the company is not expanding recklessly.
Revisions (25): Analysts have, on balance, been cutting their forecasts.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on ICCC, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 13 July 2020 | Aegis Capital | Initiates | Buy | $14 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ICCC appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 24 Aug 2026, ImmuCell Corp. returned +61.6% against +19.6% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 5% of US stocks
Cheaper than 42% of US stocks
Cheaper than 36% of US stocks
Cheaper than 27% of US stocks
Higher than 56% of US stocks
Higher than 92% of US stocks
Higher than 57% of US stocks
Higher than 85% of US stocks
Higher than 54% of US stocks
Higher than 49% of US stocks
Higher than 82% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
ImmuCell Corp. has a market value of $91.4M and an enterprise value of $95.0M.
Revenue in the twelve months to 31 Mar 2026: $29.9M. The latest quarter grew 11.5% year on year.
Net income over the same four quarters: −$545K, a −1.8% net margin.
Diluted earnings per share, trailing twelve months: $−0.06.
Free cash flow in the twelve months to 31 Mar 2026: $3.4M, after $1.1M of capital spending.
Trailing P/E: 143.7×; forward P/E: −91.5× — the forward figure prices analyst consensus estimates, not reported earnings.
ImmuCell Corp. employs 73 people — $410K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own ImmuCell Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
This item is the transcript of ImmuCell Corporation's Q2 2026 earnings call, published by Seeking Alpha. It presents the company's second-quarter earnings discussion in its own words.
Why it matters — An ICCC watcher would care because the earnings call transcript provides direct insight into the company's latest quarterly financial results and management commentary.
ImmuCell reported higher second-quarter sales and earnings, driven by increased domestic demand for its calf scours prevention products. The company also outlined plans to invest roughly $8 million to more than triple manufacturing capacity by the end of 2027.
Why it matters — For an ImmuCell watcher, the reported sales and earnings gains along with the announced capacity expansion signal ongoing product demand and preparation for greater manufacturing output in the coming years.
ImmuCell Corporation, an animal health biologics company, announced its unaudited financial results for the quarter ended June 30, 2026. The announcement was made on August 13, 2026, via GlobeNewswire.
Why it matters — ICCC watchers would care because this is the company's latest quarterly financial disclosure, providing current insight into its performance.
ImmuCell announced it will report unaudited financial results for the quarter ended June 30, 2026, after the market closes on August 13, 2026, and will host a conference call and webcast on August 14, 2026, at 9:00 AM ET to review the results.
Why it matters — This notice gives ImmuCell watchers the date and time for the company's upcoming quarterly earnings report and management's review of its recent performance.
The article discusses ImmuCell's First Defense product as its core franchise with commercial momentum across year-round dairy customers. It notes improving manufacturing yields and reallocation of Re-Tain assets towards First Defense production capacity, while raising concerns about reliance on two main distributors and product concentration.
Why it matters — An ICCC watcher would care because the article highlights positive execution on First Defense, the company's primary revenue driver, while flagging ongoing risks around customer and product concentration.
As at 22 Aug 2026, ImmuCell Corp. ranks 94 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (96 of 100).
No analyst covering ImmuCell Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ICCC are extrapolating price history, which says nothing about the business.
ImmuCell Corp. returned +61.6% over the 12 months to 24 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
ImmuCell Corporation is a biotechnology company engaged in the development, manufacture, and sale of products that improve animal health and productivity in the dairy and beef industries. The company's primary focus is on the development of products that provide alternatives to traditional antibiotics, offering innovative solutions to enhance the immune system of livestock.
The most recent item we track (Seeking Alpha, 14 Aug 2026): "ImmuCell Corporation (ICCC) Q2 2026 Earnings Call Transcript". This item is the transcript of ImmuCell Corporation's Q2 2026 earnings call, published by Seeking Alpha. It presents the company's second-quarter earnings discussion in its own words.
ImmuCell Corporation is a biotechnology company engaged in the development, manufacture, and sale of products that improve animal health and productivity in the dairy and beef industries. The company's primary focus is on the development of products that provide alternatives to traditional antibiotics, offering innovative solutions to enhance the immune system of livestock. ImmuCell’s notable product, First Defense, helps prevent scours (diarrhea) in newborn dairy and beef calves, a common ailment that can impair growth and development and lead to high mortality rates. By addressing such pervasive health challenges in the livestock sector, ImmuCell significantly impacts agricultural productivity and sustainability. Located in the United States, ImmuCell Corporation contributes to the broader biotechnology and agricultural markets by promoting healthier livestock, thereby potentially reducing the dependency on antibiotics and aligning with global trends towards more sustainable and responsible farming practices. This focus not only underscores the company’s role in animal health innovation but also highlights its importance in food safety and the agricultural supply chain.
CEO Mr. Paul F. Olivier Te Boekhorst · 73 employees · United States · https://immucell.com
